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Venous thromboembolism (VTE), comprised of deep vein
thrombosis (DVT) and pulmonary embolism (PE), has
gained increasing recognition over the last two decades as a
serious medical condition and a public health concern [1].
Since VTE is a largely preventable disorder, appropriately
focused public health initiatives can have a major impact
on its incidence. On average, about 1/1000 individuals will
develop VTE annually, with the highest incidence in the
older population [2]. Because VTE is a disease of aging we
can only expect its incidence to rise with the graying of the
population. Importantly, when VTE manifests itself as PE,
it has a high case fatality rate and PE accounts for
approximately 100,000 deaths per year [2]. Accurate
statistics, however, are difficult to acquire, possibly
because PE often develops as a complication of other
serious conditions and it often goes undiagnosed, or even
when diagnosed, death is attributed to the underlying
illness.
What has changed about VTE that has elevated its
importance in the spectrum of medical conditions? Many
factors may be responsible, including a better understand-
ing of the pathophysiology of VTE, a better recognition of
risk factors leading to VTE, and a better understanding and
recognition of hereditary and acquired thrombophilias.
Undoubtedly, however, recent improvements in the treat-
ment of VTE play an important role and make it more
important than ever that healthcare providers are well
educated about recent changes. We now have interventions
such as thrombolysis, mechanical clot retrieval, new
venous stents and vena cava filters or combinations of these
[3], some of which have been shown to improve outcomes
in those patients with the most severe forms of VTE. For
the overwhelming majority of cases, however, treatment is
based on the administration of an anticoagulant to prevent
the extension or recurrence of thrombus [4]. Heparin was
first used clinically in the 1930s followed shortly thereafter
by dicoumarol and warfarin in the 1940s, and these agents
have been the foundation of treatment of VTE until the
present time [5]. For the first time since the discovery of
the VKAs, we now have new oral anticoagulants that are
alternatives to more traditional therapies in both the acute
and long-term management of VTE [6]. These drugs
induce anticoagulation by directly targeting and binding to
specific coagulation factors and neutralizing them, a
mechanism of action entirely different from the VKAs and
one that has advantages as well as disadvantages. With
warfarin, clinicians must be familiar with the pharma-
cokinetics of only one drug, yet management is complex
and labor intensive and expert dose management is
required to achieve the best outcomes [7]. The new direct
oral anticoagulants (DOACs) are advantageous because
they are easier to manage, but like so many other medi-
cation classes, there are now 4 such drugs on the market,
each with their own indications, doses and pharmacoki-
netics [8]. Thus, the complexity of managing oral antico-
agulant therapy persists, whether with the VKAs or the
DOACs.
There are many therapeutic decision points in the course
of VTE treatment. To aid clinicians, professional groups
have published treatment guidelines based on the best
medical evidence or rendered consensus opinions when
good quality evidence is lacking. The most prominent of
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these guidelines are those published by the American
College of Chest Physicians, starting in 1989 with updates
every 3–4 years, the last being in 2012. With the rapidly
changing management of VTE, in part, spurred by the
introduction of the DOACs, the Anticoagulation Forum
detected an urgent need for practical knowledge about the
changing management paradigm. The Anticoagulation
Forum is the largest peer organization of anticoagulation
service providers in North America (ACForum.org). Its
6000? members are comprised of physicians, nurses, and
pharmacists representing over 2000 anticoagulation ser-
vices (clinics). The AC Forum’s goal is to create a com-
munity where physicians, pharmacists and nurses can
access the latest research, engage in educational programs,
and find tools to evaluate and enhance their practice.
In an effort to bring practical and implementable infor-
mation to its members and the provider community at
large, the AC Forum initiated this guidance project by
assembling experts in the disciplines of VTE research,
education and care, asking them to consider practical
everyday questions about the treatment of VTE using the
best medical evidence and existing guidelines, but not
hesitating to offer consensus opinions when high-quality
evidence is not available. This special issue of the Journal
of Thrombosis and Thrombolysis includes 12 manuscripts
focused on the epidemiology and management of VTE
with a particular emphasis on the management of drugs
employed in its treatment, with both traditional agents as
well as the new DOACs.
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